NEW YORK (AP) -- Drug developer Pfizer Inc. said Friday its potential rheumatoid arthritis drug met its key treatment goals in a late-stage study.
The company said the drug tofacitinib, formerly called tasocitinib, met its key goals of reducing signs and symptoms of the condition in a six-month period. Rheumatoid arthritis is a chronic inflammatory disease typically affecting joints.
Tofacitinib is a key developing drug for Pfizer and is also being studied as a potential treatment for psoriasis, inflammatory bowel disease, and renal transplant. A topical version of the drug is being studied as a psoriasis treatment and a dry eye disease treatment.
Pfizer said a full analysis of the data will be submitted to a future scientific meeting.
In early trading Friday, Pfizer shares were down 2 cents to $19.75.
The company said the drug tofacitinib, formerly called tasocitinib, met its key goals of reducing signs and symptoms of the condition in a six-month period. Rheumatoid arthritis is a chronic inflammatory disease typically affecting joints.
Tofacitinib is a key developing drug for Pfizer and is also being studied as a potential treatment for psoriasis, inflammatory bowel disease, and renal transplant. A topical version of the drug is being studied as a psoriasis treatment and a dry eye disease treatment.
Pfizer said a full analysis of the data will be submitted to a future scientific meeting.
In early trading Friday, Pfizer shares were down 2 cents to $19.75.
